

PROGENICS PHARMACEUTICALS INC
Form SC 13G/A
January 16, 2019

1/16/2019

Securities and Exchange Commission
450 Fifth Street NW
Washington, DC 20549

RE: Schedule 13G
Progenics Pharmaceuticals, Inc.
As of 12/31/2018

Gentlemen:

In accordance with Section 13(d)(5) of the Securities Exchange Act of 1934, attached please find a copy of Schedule 13G for the above named company showing beneficial ownership of 5% or more as of 12/31/2018 filed on behalf of Eagle Asset Management, Inc.

Very truly yours,

Damian Sousa
Vice President
Chief Compliance Officer
DS:CC
Enclosures

cc: Office of the Corporate Secretary
Progenics Pharmaceuticals, Inc.
One World Trade Center, 47th Floor
New York, NY 10007

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G

Under the Securities Exchange Act of 1934

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

(Amendment No. 3)*

Progenics Pharmaceuticals, Inc.
(Name of Issuer)

Common Stock
(Title of Class of Securities)

743187106
(CUSIP Number)

Check the following box if a fee is being paid with this statement _____. (A fee is not required only if the filing person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 5 Pages

CUSIP NO. 743187106

13G

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Eagle Asset Management, Inc. 59-2385219

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) _____
(B) _____

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

State of Florida

NUMBER OF SHARES BENEFICIALLY OWNED 5 SOLE VOTING POWER 4,495,365 6 SHARED VOTING POWER - - -

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

AS OF	
12/31/18	7 SOLE DISPOSITIVE POWER
BY EACH	4,495,365
REPORTING	8 SHARED DISPOSITIVE POWER
PERSON WITH	- - -

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,495,365

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_____]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

5.32%

12 TYPE OF REPORTING PERSON*

IA

Page 2 of 5 Pages

Item 1(a) Name of Issuer:
Progenics Pharmaceuticals, Inc.

Item 1(b) Address of Issuer's Principal Executing Offices:
One World Trade Center, 47th Floor
New York, NY 10007

Item 2(a) Name of Person Filing:
Eagle Asset Management, Inc.

Item 2(b) Address of Principal Business Office:
880 Carillon Parkway
St. Petersburg, Florida 33716

Item 2(c) Citizenship:
Florida

Item 2(d) Title of Class of Securities:

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

Common Stock

Item 2(e) CUSIP Number:
743187106

Item 3 Type of Reporting Person:

(e) Investment Adviser registered under Section 203 of the Investment Advisors Act of 1940

Page 3 of 5 Pages

Item 4 Ownership as of 12/31/18

(a) Amount Beneficially Owned:

4,495,365 shares of common stock beneficially owned including:

No. of Shares	
Eagle Asset Management, Inc.	4,495,365

(b) Percent of Class: 5.32

(c) Deemed Voting Power and Disposition Power:

(i)	(ii)	(iii)	(iv)
Deemed to have Sole Power to Vote or to Direct to Vote	Deemed to have Shared Power to Vote or to Direct to Vote	Deemed to have Sole Power to Dispose or to Direct the Disposition	Deemed to have Shared Power to Dispose or to Direct the Disposition

Eagle Asset Management, Inc.	4,495,365	----	4,495,365	----
------------------------------	-----------	------	-----------	------

Item 5 Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

(___)

Item 6 Ownership of More than Five Percent on Behalf of Another Person:

N/A

Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form SC 13G/A

N/A

Page 4 of 5 Pages

Item 8 Identification and Classification of Members of the Group: N/A

Item 9 Notice of Dissolution of Group: N/A

Item 10 Certification:

By signing below I certify that to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: 1/16/19

EAGLE ASSET MANAGEMENT, INC.

Damian Sousa
Vice President
Chief Compliance Officer

Page 5 of 5 Pages